aTyr Pharma Inc
ATYR4.815USD
+0.115+2.45%
交易中 （美東）報價延遲15分鐘
428.55M總市值
虧損本益比TTM
關於 aTyr Pharma Inc 公司
aTyr Pharma, Inc. 是一家臨牀階段的生物技術公司。該公司正在利用情報將 tRNA 合成酶生物學轉化爲治療纖維化和炎症的新療法。其主要治療候選藥物是 efzofitimod，這是一種生物免疫調節劑，處於臨牀開發階段，用於治療間質性肺病 (ILD)，這是一組可導致肺部炎症和纖維化或瘢痕形成的免疫介導疾病。Efzofitimod 是一種 tRNA 合成酶衍生療法，可通過神經纖毛蛋白-2 (NRP2) 選擇性調節活化的髓系細胞，以在不抑制免疫的情況下解決異常炎症並防止纖維化進展。ATYR0101 是一種源自天冬氨酰-tRNA 合成酶 (DARS) 結構域的融合蛋白。ATYR0101 直接與潛伏轉化生長因子 β 結合蛋白 1 (LTBP1) 結合，後者調節轉化生長因子 β (TGFb)。其 ATYR0750 是一種源自丙氨酰-tRNA 合成酶 (AARS) 結構域的融合蛋白。
公司簡介
公司代碼ATYR
公司名稱aTyr Pharma Inc
上市日期May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
員工數量56
證券類型Ordinary Share
年結日May 07
公司地址10240 Sorrento Valley Road
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編92121
電話18587318389
網址https://www.atyrpharma.com/
公司代碼ATYR
上市日期May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric S. Benevich
Mr. Eric S. Benevich
Independent Director
Independent Director
--
--
Ms. Nancy E. Denyes, J.D.
Ms. Nancy E. Denyes, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
股東類型
持股股東
佔比
Investment Advisor
27.84%
Investment Advisor/Hedge Fund
20.75%
Hedge Fund
20.46%
Individual Investor
2.23%
Research Firm
1.92%
Pension Fund
0.20%
Bank and Trust
0.05%
Venture Capital
0.02%
Other
26.52%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
160
65.39M
73.47%
+2.57M
2025Q1
162
64.83M
72.99%
-691.51K
2024Q4
140
57.60M
68.66%
-6.81M
2024Q3
117
50.41M
67.53%
-11.03M
2024Q2
113
50.68M
74.24%
-3.06M
2024Q1
111
44.35M
66.05%
-8.23M
2023Q4
110
43.49M
75.20%
-5.05M
2023Q3
109
43.22M
76.15%
+288.84K
2023Q2
108
41.84M
78.83%
+2.15M
2023Q1
98
40.77M
78.21%
+15.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Federated Hermes Global Investment Management Corp.
14.67M
16.48%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
12.89M
14.49%
+796.10K
+6.58%
Mar 31, 2025
The Vanguard Group, Inc.
4.01M
4.5%
+401.81K
+11.15%
Mar 31, 2025
Octagon Capital Advisors LP
3.55M
3.99%
+2.65M
+294.67%
Mar 31, 2025
Point72 Asset Management, L.P.
2.84M
3.2%
-2.04M
-41.76%
Mar 31, 2025
Tikvah Management LLC
2.46M
2.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.73M
1.95%
+945.24K
+119.98%
Mar 31, 2025
Woodline Partners LP
1.68M
1.89%
-1.41K
-0.08%
Mar 31, 2025
UBS Financial Services, Inc.
1.61M
1.81%
+1.38M
+600.20%
Mar 31, 2025
Millennium Management LLC
1.60M
1.8%
+1.23M
+334.53%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
iShares Micro-Cap ETF
0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0%
查看更多
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.42%
iShares Micro-Cap ETF
佔比0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.03%
ProShares Hedge Replication ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
